HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.